A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-C [Studio di fase III di valutazione di BMS-790052 (Daclatasvir) a confronto con Telaprevir in combinazione con Peg-interferone Alfa-2a e Ribavirina (RBV) in soggetti Naive al trattamento affetti da Epatite-C cronica]

Trial Profile

A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-C [Studio di fase III di valutazione di BMS-790052 (Daclatasvir) a confronto con Telaprevir in combinazione con Peg-interferone Alfa-2a e Ribavirina (RBV) in soggetti Naive al trattamento affetti da Epatite-C cronica]

Completed
Phase of Trial: Phase III

Latest Information Update: 31 May 2017

At a glance

  • Drugs Daclatasvir (Primary) ; Peginterferon alfa-2a; Ribavirin; Telaprevir
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Acronyms COMMAND-3
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 05 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Feb 2013 Planned End Date changed from 1 Jun 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov.
    • 04 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top